Alliances
Collaboration with Silence Therapeutics aims to develop novel, targeted treatments to address significant unmet need
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 30, 2020.
The two companies plan to focus their efforts on targeting several rare diseases.
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.
Sanofi Pasteur and Translate Bio have partnered to develop a novel messenger RNA vaccine for COVID-19, the disease caused by the novel coronavirus.
Specifically, they will be looking at ways to improve processes by speeding up and reducing the cost of manufacturing.
A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.
Under terms of the agreement, Astellas will make an upfront cash payment of $80 million to CytomX.
The two companies will focus on BioNTech’s BNT162, an mRNA-based vaccine candidate.
The companies intend to push the vaccine candidate into human trials by April of this year, subject to regulatory approval.
PRESS RELEASES